How Beliefs in Biological Differences Can Undergird Racial and Policy Attitudes
By Carson Byrd,
USAPP
| 08. 24. 2015
Untitled Document
It has been 15 years since then President Bill Clinton and leading scientists of the Human Genome Project made their highly-acclaimed proclamations that race at the genetic level does not exist. At the time this supported the long-held narrative of scholars that the once prominent beliefs in biological determinism (race as a genetic reality) and racial essentialism (human behavior is anchored in group-based biological differences) had been all but completely laid to rest in the archives of history, particularly after the fall of the Nazi regime and the end of the Holocaust after World War II. However, these beliefs in race and genetics may be making a comeback as genetic and genomic research gains in popularity and media visibility. As sociologist Lawrence Bobo and colleagues recently note in their analysis of survey data, there is a recent uptick the last decade in the belief that there are innate (i.e., biological or genetic) racial differences that drive racial inequality.
Many social scientists argue that since the peak of the Civil Rights Movement in the 1960s whites in the U.S...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...